2024: First European gene therapy, HEMGENIX®, approved for hemophilia B treatment in France.
On July 4, 2024, CSL Behring administered HEMGENIX® (etranacogene dezaparvovec), the first gene therapy approved in Europe for hemophilia B treatment, to two patients in France. This marks the first gene therapy treatment for the disease in Europe and allows patients to produce their own Factor IX, potentially reducing the risk of bleeding. HEMGENIX® was granted conditional marketing authorization by the European Commission and is now available in multiple countries, including the US, Canada, and the UK.
July 04, 2024
7 Articles